{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:48:06Z","timestamp":1789015686504,"version":"build-2803163510"},"reference-count":31,"publisher":"ECO-Vector LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["consortium-psy.com"],"crossmark-restriction":false},"short-container-title":["Consortium Psychiatricum"],"abstract":"<jats:p>Over the past three decades, the definition and diagnostic boundaries of Alzheimers disease (AD) have been repeatedly revised due to significant progress in understanding of the pathogenesis of neurodegeneration associated with Alzheimers disease and in the development of high-tech diagnostic methods. The current approach to AD diagnostics relies on the detection of biomarkers that reflect two main neuropathological processes involved in the primary neurodegeneration that underlies AD: abnormal amyloidogenesis, and neuronal degeneration. The currently available diagnostic tools are limited to the detection of cerebrospinal biomarkers and\/or assessment of the abnormal amyloid and tau protein burden in the brain via amyloid and tau positron emission tomography (PET) ligands. Practical implementation (mostly in the research field) of the biological model of AD diagnosis has led to a significant expansion of its diagnostic boundaries with the inclusion of predementia AD stages: asymptomatic and symptomatic, the latter is clinically corresponding to amnestic mild cognitive impairment (aMCI-amnestic mild cognitive impairment). On the one hand, this approach significantly expands the possibilities to study and use preventive technologies aiming to avert or delay the progression of predementia cognitive impairment to dementia but, on the other, it is associated with a number of negative implications from both the clinical and ethical points of view. A significant limitation of purely biological diagnosis of AD based on biomarker levels is due to the low prognostic value of biomarkers, which can cause diagnostic confusion in certain circumstances. Moreover, since the future evolution of the asymptomatic stage is not yet clear and there are still no reliable ways to prevent the cognitive and behavioral symptoms associated with AD, disclosure of stressful information about this terrifying diagnosis to patients can cause irreversible damage by triggering depressive disorder, which is a risk factor of AD itself.\r\nThe current knowledge about AD prognosis in amyloid-positive cognitively unimpaired patients is insufficient.The most adequate approach to early AD diagnostics appears to be the clinical and biological model, as recommended by the International Working Group (IWG 2021), which requires a combination of the clinical AD phenotype and the detection of biomarkers specific to this disease.\r\nThe article discusses the potential directions for the development of biological diagnostic methods, including those based on the so-called peripheral (serum) biomarker technologies and promising directions for the development of biological methods of secondary AD prevention.<\/jats:p>","DOI":"10.17816\/cp152","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T14:13:56Z","timestamp":1649254436000},"page":"8-15","update-policy":"https:\/\/doi.org\/10.17816\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":2,"title":["The Evolution of Diagnostic Boundaries of Alzheimer\u2019s Disease and Novel Therapeutic Options"],"prefix":"10.17816","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6683-0240","authenticated-orcid":false,"given":"Svetlana","family":"Gavrilova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7284","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12328"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 1984;34:939\u201344.","DOI":"10.1212\/WNL.34.7.939"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(07)70178-3"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(10)70223-4"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.focus.11.1.96"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv199"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30029-2"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)30125-9"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0510-3"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2017.05.058"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00066-1"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0000000000000052"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1109\/JBHI.2020.2984355"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4505720"},{"key":"ref16","unstructured":"Fedorova YB, Zakharova NV, Bugrova AE, Indeikina MI, Brzhozovskii AG, Popov IA, Kononikhin AS, Kolykhalov IV, Gavrilova SI, Nikolaev EN. Issledovanie izmenenii proteoma plazmy krovi, assotsiirovannykh s bolezn\u2019yu Al\u2019tsgeimera. XVII s\u201dezd psikhiatrov Rossii. In: Neznanov NG, editor. Interdistsiplinarnyi podkhod k komorbidnosti psikhicheskikh rasstroistv na puti k integrativnomu lecheniyu; 2021 May 15\u201318; Saint-Petersburg. Saint-Petersburg: NMITs PN im. V.M. Bekhtereva; 2021. p.182\u2013184. Russian."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2217\/bmm.12.48"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro2015115112110-117"},{"key":"ref19","unstructured":"Alesenko AV, Gavrilova SI, Karatasso YI, Fedorova YB, Tiganov AS. Tseramidy \u2014 potentsial\u2019nye biomarkery bolezni Al\u2019tsgeimera. Potentsial\u2019naya rol\u2019 sfingolipidov v neiropatogeneze bolezni Al\u2019tsgeimera. Psychiatry (Moscow) 2014;(1):13\u201320. Russian."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20171178127-38"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2007.01159.x"},{"key":"ref22","unstructured":"Androsova LV, Klyushnik TP, Zozulya SA, Mikhaylova NM. Leukocyteelastase and interleukins in Alzheimer\u2019s disease. Diseases 2013;11(1):1173. Russian."},{"key":"ref23","unstructured":"Klyushnik TP, Androsova LV, Mikhailova NM, Sokolov AV, Kostevich VA, Zakharova ET, Vasil\u2019ev VB. Potentsial\u2019nye markery bolezni Al\u2019tsgeimera, assotsiirovannye s vospaleniem. Psychiatry (Moscow) 2014;(1):28\u201334. Russian."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro202112110216"},{"key":"ref25","unstructured":"Klyushnik TP, Zozulya SA, Androsova LV, Sarmanova ZV, Otman IN, Panteleeva GP, Oleichik IV, Kopeiko GI, Borisova OA, Abramova LI, et al. Laboratornaya diagnostika v monitoringe patsientov s endogennymi psikhozami. Moscow: Meditsinskoe informatsionnoe agentstvo; 2016. Russian."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/med.21722"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2012.48(Suppl.A).1739716"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s007020170058"},{"key":"ref29","unstructured":"Akai F, Hiruma S, Sato T, Iwamoto N, Fujimoto M, Ioku M, Hashimoto S. Neurotrophic factor-like effect of FPF1O7O on Septal cholinergic neurons after transections of fimbria-fornix in the rat brain. Histol Histopathol 1992;7(2):21\u201321."},{"key":"ref30","unstructured":"Gavrilova SI, Kolykhalov IV, FedorovaYB, Selezneva ND, Kalyn YB, Roshchina IF, Odinak MM, Emelin AY, KashinAV, Gustov AV, et al. Vozmozhnosti preventivnoi terapii bolezni Al\u2019tsgeimera: rezul\u2019taty 3-letnego prospektivnogo sravnitel\u2019nogo issledovaniya effektivnosti i bezopasnosti kursovoi terapii tserebrolizinom i kavintonom u pozhilykhpatsientov s sindromom myagkogo kognitivnogo snizheniya. Zhurnal nevrologii i psikhiatrii im SS Korsakova 2010;(1):68\u201375. Russian."},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Gavrilova SI, Ponomareva EV, Krynskii SA, Malashenkova IK, Khailov NA, Ogurtsov DP, Chekulaeva EI, Didkovskii NA. Immunologicheskie markery dolgosrochnykh effektov terapii u patsientov s sindromom myagkogo kognitivnogo snizheniya. Meditsinskii akademicheskii zhurnal 2019;19(1):84\u201386. Russian.","DOI":"10.17816\/MAJ191S184-86"}],"container-title":["Consortium Psychiatricum"],"original-title":[],"link":[{"URL":"https:\/\/consortium-psy.com\/jour\/article\/viewFile\/152\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/consortium-psy.com\/jour\/article\/viewFile\/152\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T04:21:30Z","timestamp":1719462090000},"score":1,"resource":{"primary":{"URL":"https:\/\/consortium-psy.com\/jour\/article\/view\/152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,15]]}},"URL":"https:\/\/doi.org\/10.17816\/cp152","relation":{},"ISSN":["2713-2919","2712-7672"],"issn-type":[{"value":"2713-2919","type":"electronic"},{"value":"2712-7672","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,15]]}}}